• Tenon Now Holds 9 Granted Patents and 26 Pending Applications for the Catamaran® SI Joint Fusion System Worldwide

LOS GATOS, CA / ACCESSWIRE / September 19, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the United States Patent and Trademark Office ("USPTO") issued three (3) Notices of Allowance for U.S. Patent Application Numbers 17,469,132 and 17/468,811, both entitled "Sacroiliac Joint Stabilization Prostheses", and 18/612,032, entitled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints". The U.S. patents based on the applications should thus issue within the next ninety (90) days.

U.S. Pat. App. Nos. 17,469,132 and 17/468,811 are directed to SI joint prostheses that include unique drug delivery compositions that aid in bone growth about and within the prostheses when implanted in a SI joint. U.S. Pat. App. No. 18/612,032 is directed to SI joint prostheses with unique configurations to correct failed SI joint stabilization with alternative commercial SI joint implants without requiring removal of the failed implant.

The three (3) U.S. patents, when issued, will further enhance the Company's growing patent portfolio for its Catamaran® SI Joint implant system, which now comprises nine (9) issued U.S. and foreign (International) patents, and twenty-six (26) pending U.S. and foreign patent applications.

"A critical component of our growth strategy is pursuing and obtaining effective intellectual property protection for the key technology, processes and devices of our Catamaran® SI Joint Fusion System. As we advance our commercialization efforts, we are pleased to have reinforcement by the USPTO, which has again provided us with Notice of Allowances for these three new patents," said Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical. "As we continue to aggressively develop our intellectual property, we have added a number of new patents and patent applications, including the three (3) soon to be issued U.S. patents and three (3) recently filed U.S. patent applications. IP efforts such as these serve to further solidify our international patent portfolio, protect our technology platform, strengthen our competitive position in the industry, and underscore our commitment to innovation in advancing a less invasive approach to the SI joint."

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022 Tenon is focused on two commercial opportunities with its System in the SI Joint market which includes: 1) Primary SI Joint procedures, and 2) Revision procedures of failed SI Joint implants. For more information, please visit www.tenonmed.com.

The Tenon Medical logo Tenon Medical, and Catamaran are registered trademarks of Tenon Medical, Inc. MAINSAIL is a trademark of Tenon Medical

Safe Harbor

This press release contains "forward-looking statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," "aims," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

IR Contact:

Shannon Devine / Rory Rumore
203-741-8811
MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.